ABSTRACT
KEY WORDS: monoclonal antibodies, lintuzumab, acute myeloid leukemia, gentuzumab ozogamicin
Monoclonal antibodies (mAbs) are a relatively new class of biologic agents that target specic receptors on cancer cells. These types of drugs have shown signicant improvement in the treatment of certain hematologic disorders. Leukemias represent an ideal target for the development of such therapies as malignant cells are easily accessible in the blood and bone marrow of these patients. Antibodies against CD33, a cell-surface glycoprotein, are the best example. The humanized anti-CD33 lintuzumab has modest activity on acute myeloid leukemia (AML), but it can eliminate minimal residual disease in acute promyelocytic leukemia. Gentuzumab ozogamicin (GO), an anti-CD33-calicheamicin conjugate has activity in patients with relapsed
Abstract .................................................................................................................. 211 Introduction ............................................................................................................ 212 Anti-CD33 mAb, Lintuzumab ............................................................................... 212 Anti-CD33 Conjugates, Gentuzumab Ozogamicin ................................................ 214 Anti-CD44 .............................................................................................................. 216 Anti-CD123 ............................................................................................................ 216 Radiolabeled Antibodies ........................................................................................ 216
Radiolabeled Anti-CD33 ................................................................................... 217 Radiolabeled Anti-CD45 ................................................................................... 218 Radiolabeled Anti-CD66 ................................................................................... 218
Conclusions ............................................................................................................ 218 References .............................................................................................................. 219
AML and appears promising in combination with chemotherapy for newly diagnosed patients.
